<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5839</td>
<td>Highlights of This Issue <strong>SPECIAL FEATURES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCR Translations</td>
<td></td>
</tr>
<tr>
<td>5841</td>
<td><strong>Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma</strong></td>
<td>Michael R. Harrison and Daniel J. George</td>
</tr>
<tr>
<td></td>
<td><strong>See article p. 6021</strong></td>
<td></td>
</tr>
<tr>
<td>5844</td>
<td><strong>Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone</strong></td>
<td>James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson</td>
</tr>
<tr>
<td></td>
<td><strong>ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease</strong></td>
<td>Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huet-Chi Wen, and Julio A. Aguirre-Ghiso</td>
</tr>
<tr>
<td>5858</td>
<td><strong>Thrombotic Microangiopathy with Targeted Cancer Agents</strong></td>
<td>John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman</td>
</tr>
<tr>
<td></td>
<td><strong>Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System</strong></td>
<td>Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Billouin, Wenhwai Horng, William N. Rom, Steven M. Albeda, Michael K. Showe, and Louise C. Showe</td>
</tr>
<tr>
<td></td>
<td><strong>ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy</strong></td>
<td>Sarah Minner, Malaika Enodien, Hüseyin Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Müller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schlüter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graefen, Guido Sauter, and Thorsten Schlomm</td>
</tr>
<tr>
<td></td>
<td><strong>Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer</strong></td>
<td>Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo</td>
</tr>
<tr>
<td>5878</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5890</td>
<td><strong>Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma</strong></td>
<td>Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev</td>
</tr>
<tr>
<td>5917</td>
<td><strong>Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody</strong></td>
<td>Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan</td>
</tr>
<tr>
<td>5926</td>
<td><strong>Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance</strong></td>
<td>Kelly M. Quesnelle and Jennifer R. Grandis</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: PRECLINICAL**

**ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease**

Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huet-Chi Wen, and Julio A. Aguirre-Ghiso

**ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy**

Sarah Minner, Malaika Enodien, Hüseyin Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Müller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schlüter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graefen, Guido Sauter, and Thorsten Schlomm

**Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer**

Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo

**Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma**

Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev

**Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants**


**Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody**

Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan

**Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance**

Kelly M. Quesnelle and Jennifer R. Grandis
Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes

Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Moldrem, Michael Wang, Satvya S. Neelapu, and Larry W. Kwak

Curcumin Treatment Suppresses IKKb Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study

Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marilene B. Wang

Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor

Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærsgaard Jørgensen, Adam Hey, and Michael Kragh

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bel-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents

Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnaud, Anne Moreau, Philippe Moreau, Catherine Pellaudeau-Decesnynek, Martine Amiot, and Steven Le Gouill

Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials

AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, and Brigitte C. Widemann

A Polymorphic –844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer

Wen-Wei Sung, Yao-Chen Wang, Ya-Wen Cheng, Ming-Ching Lee, Kun-Tu Yeh, John Wang, Chih-Yi Chen, and Huei Lee

Specific PET Imaging of xc- Transporter Activity Using a 18F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism


A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors


Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer

Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles

See commentary p. 5841

Prognostic Impact of ΔTap73 Isoform Levels and Their Target Genes in Colon Cancer Patients

Beatriz Soldevilla, Raquel Díaz, Javier Silva, Yolanda Campos-Martín, Concepción Muñoz, Vanesa García, José M García, Cristina Peña, Mercedes Herrera, Marta Rodríguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez

Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma

Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busesaid, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, and Patricia LoRusso
ABOUT THE COVER

Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.